Brief: CAPLYTA(Lumateperone)Shows Significant And Rapid Improvement In Bipolar Mania In Pivotal Phase 3 Study

Johnson & Johnson

21/09/2026 13:36

Sept 21 (Reuters) - Johnson & Johnson JNJ.N:
CAPLYTA® (LUMATEPERONE) SHOWS SIGNIFICANT AND RAPID IMPROVEMENT IN BIPOLAR MANIA IN PIVOTAL PHASE 3 STUDY
J&J - CAPLYTA DEMONSTRATES STATISTICALLY SIGNIFICANT RAPID REDUCTION IN MANIC SYMPTOMS AT WEEK 3
J&J - CAPLYTA WELL-TOLERATED; DRY MOUTH AND NAUSEA MOST COMMON ADVERSE EVENTS
Source text: ID:nPnbbdbJ6a
Further company coverage: JNJ.N

 ((Reuters.Briefs@thomsonreuters.com;))